Researchers develop Lassa fever treatment effective eight days after infection

September 5, 2017, University of Texas Medical Branch at Galveston
Credit: University of Texas Medical Branch at Galveston

A collaborative team of scientists, led by a group at The University of Texas Medical Branch at Galveston, have successfully protected nonhuman primates against one of the most deadly viruses in the world, Lassa fever, eight days after they became infected. The findings are now available in Nature Medicine.

The virus, for which there are no approved vaccines or treatments, infects hundreds of thousands of people every year and is estimated to kill approximately 34 percent of those infected, according to the Centers for Disease Control and Prevention. Also, military and science experts say that the virus could be used as a biological terror weapon.

"In this study, we tested a combination of three by giving them to beginning up to eight days following exposure to a lethal amount of Lassa virus," said UTMB's Thomas Geisbert, a professor in the Department of Microbiology and Immunology. "We found that the treatments were well-tolerated and provided 100 percent protection from Lassa fever. Without treatment, the animals show evidence of the virus in their bodies by day four after exposure."

Monoclonal antibodies are widely used for treating cancers and autoimmune diseases and more than 45 different types are approved by the U.S. Food and Drug Administration and European Medicines Agency.

"The fact that the treatment was able to rescue 100 percent of the animals more than a week after infection with Lassa virus suggests that this therapy may benefit patients with Lassa fever in West Africa, who often arrive at the clinic at a late stage of disease," said Robert Garry, a professor in the department of microbiology and immunology at Tulane. "We are accelerating further development so that this promising treatment can be introduced into clinics in West Africa and deployed as a deterrent against the use of Lassa virus as a bioweapon."

Recently, travelers on commercial airlines have imported Lassa fever into Europe and the U.S., highlighting the potential for spread of the disease. The disease is classified as a Category A pathogen - an organism that poses the highest risk to national security and public health - by several U.S. government agencies because of the concern for deliberate misuse.

Explore further: Lassa fever kills two in Lagos, 100 others on watch: hospital

More information: Chad E Mire et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever, Nature Medicine (2017). DOI: 10.1038/nm.4396

Related Stories

Lassa fever kills two in Lagos, 100 others on watch: hospital

August 9, 2017
Two people in Lagos have died and a hundred medical workers have been placed under observation after a flare-up of Lassa fever, a cousin of the deadly Ebola virus, officials said Wednesday.

Antiviral favipiravir successfully treats Lassa virus in guinea pigs

October 13, 2015
Favipiravir, an investigational antiviral drug currently being tested in West Africa as a treatment for Ebola virus disease, effectively treated Lassa virus infection in guinea pigs, according to a new study from National ...

Monoclonal antibody cures Marburg infection in monkeys

April 5, 2017
An antibody treatment successfully protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected, according to the latest findings of a collaborative team from The ...

Nine people suspected dead of Lassa fever in Benin

February 2, 2016
As the world ramps up its fight against the Zika virus, West Africa is battling to contain a growing outbreak of Lassa fever with nine people in Benin reported dead, a health official told AFP Tuesday.

Studies of US Lassa fever patient offer clues about immune response, viral persistence

June 22, 2017
When an American nurse working in West Africa became ill with Lassa fever and was evacuated to the U.S. for treatment in 2016, it provided a rare opportunity. With the consent of the patient, researchers were able to closely ...

Two dead from Ebola-like Lassa fever in Benin: officials

November 21, 2014
Two people have died in Benin from the Ebola-like virus Lassa fever, the country's government and a World Health Organization (WHO) official said on Friday.

Recommended for you

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism

December 11, 2018
Treatment with active vitamin D did not decrease cardiovascular events in kidney patients undergoing hemodialysis, according to a research group in Japan. They have reported their research results in the December 11 issue ...

Human antibody discovery could save lives from fungal killer

December 11, 2018
A new way to diagnose, treat and protect against stealth fungal infections that claim more than 1.5 million lives per year worldwide has been moved a step closer, according to research published in Nature Communications.

Dialysis patients at risk of progressive brain injury

December 10, 2018
Kidney dialysis can cause short-term 'cerebral stunning' and may be associated with progressive brain injury in those who receive the treatment for many years. For many patients with kidney failure awaiting a kidney transplant ...

Silicosis is on the rise, but is there a therapeutic target?

December 6, 2018
Researchers from the CNRS, the University of Orléans, and the company Artimmune, in collaboration with Turkish clinicians from Atatürk University, have identified a key mechanism of lung inflammation induced by silica exposure, ...

PET scans to optimize tuberculosis meningitis treatments and personalize care, study finds

December 6, 2018
Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain—or tuberculosis meningitis (TBM)—is often deadly, always hard to treat, and a particular ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.